USFDA Guidance: Leveraging Prior Knowledge in Genome Editing Gene Therapy Development

As genome editing technologies continue to advance, sponsors are increasingly developing innovative gene therapies targeting rare, serious, and life-threatening diseases. These programs often involve complex manufacturing processes, extensive nonclinical studies, sophisticated analytical testing, and lengthy clinical development timelines.

To support more efficient development pathways, the FDA released the draft guidance, Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing. The guidance outlines how sponsors may utilize existing scientific, manufacturing, nonclinical, and clinical knowledge to streamline development activities, reduce duplication of effort, and support regulatory submissions.

Understanding Prior Knowledge

The guidance identifies two major categories of prior knowledge that may be considered during product development.

Public Knowledge

Public knowledge includes scientific information that is broadly accepted by experts and supported by reliable evidence.

Examples include:

• Peer-reviewed publications

• Scientific literature

• Regulatory guidance documents

• Industry standards

• Pharmacopeial references

Platform Knowledge

Platform knowledge refers to experience gained from developing similar products using common technologies, manufacturing processes, delivery systems, or analytical methods.

Potential sources include:

Source	Example
Internal Company Experience	Previous products using the same platform
Master Files	CDMO and supplier data
Public Information	Published platform knowledge
Industry Collaborations	Shared databases and consortia

FDA emphasizes that all leveraged information should be scientifically relevant and appropriately justified.

Leveraging Prior Knowledge in CMC Development

One of the most significant opportunities for leveraging prior knowledge exists within Chemistry, Manufacturing, and Controls (CMC).

The guidance suggests that sponsors may leverage existing knowledge when sufficient similarities exist between products, manufacturing processes, formulations, and genome editing components.

Examples of CMC Information That May Be Leveraged

Area	Potential Application
Analytical Methods	Platform assays and validation strategies
Lot Release Specifications	Testing approaches and acceptance criteria
Stability Programs	Storage conditions and stability protocols
Comparability Studies	Manufacturing change assessments
Process Validation	Platform manufacturing data
Manufacturing Facilities	Environmental monitoring and contamination controls

This approach can help reduce development burden while maintaining product quality and regulatory compliance.

Leveraging Nonclinical Knowledge

FDA recommends a risk-based approach when considering nonclinical data leveraging.

Existing information may support development activities when product similarities are adequately demonstrated.

Potential sources include:

• In vitro studies

• In silico assessments

• Animal studies

• Published scientific literature

• Previous development programs

The extent of leveraging depends on factors such as product design, editing mechanism, delivery system, manufacturing process, and intended clinical use.

Considerations for Genome Editing Products

The guidance provides recommendations for both ex vivo and in vivo genome editing therapies.

Ex Vivo Genome Editing Products

Potential areas for leveraging include:

• Cell processing methods

• Cell expansion platforms

• Potency assays

• Cell characterization techniques

• Manufacturing controls

In Vivo Genome Editing Products

Potential opportunities may exist when products share similar:

• Genome editing technologies

• Delivery vectors

• Lipid nanoparticle systems

• Routes of administration

• Manufacturing platforms

FDA notes that product-specific differences must always be carefully evaluated before leveraging existing data.

Leveraging Bioinformatics and Genomic Data

The increasing use of next-generation sequencing (NGS) has created opportunities to leverage bioinformatics knowledge across multiple development programs.

Examples include:

• Off-target assessment strategies

• Sequencing methodologies

• Bioinformatics analysis pipelines

• Data quality standards

• Computational prediction tools

However, because genome editing outcomes are often highly sequence-specific, certain genomic datasets may not be appropriate for direct transfer between products targeting different genomic regions.

Leveraging Clinical Experience

Existing clinical knowledge may also support future development programs.

Potential applications include:

• Dose selection

• Safety monitoring strategies

• Biomarker selection

• Clinical endpoint development

• Long-term follow-up planning

Sponsors may additionally consider the use of:

• Natural history studies

• Real-world evidence (RWE)

• Previous clinical trial experience

FDA encourages sponsors to discuss these approaches early during development.

Importance of Early FDA Engagement

A recurring theme throughout the guidance is the importance of early communication with FDA.

Sponsors considering knowledge-leveraging strategies are encouraged to engage with the Agency through:

• INTERACT meetings

• Pre-IND meetings

• Early development discussions

Early regulatory feedback can help ensure that proposed leveraging approaches are scientifically acceptable and aligned with FDA expectations.

As genome editing technologies continue to evolve, the ability to strategically leverage prior knowledge may help sponsors accelerate innovation, improve regulatory efficiency, and bring transformative therapies to patients more quickly.

References

1. FDA Draft Guidance for Industry: Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing (June 2026)